- Workshop presentation
- Open Access
Detection of increased coronary microvascular permeability with MRI T1 mapping and gadolinium-labeled albumin
© Cui et al. 2016
- Published: 27 January 2016
- Contrast Agent
- Partition Coefficient
- Agent Concentration
- Adverse Cardiac Event
Conditions such as obesity and diabetes lead to coronary microvascular disease and, subsequently, an increased risk of adverse cardiac events. Increased microvascular permeability is thought to be an early biomarker of coronary microvascular disease. While prior studies have used MRI with gadolinium-labeled albumin, a macromolecular contrast agent, to detect myocardial infarction, we hypothesized that MRI T1 mapping with gadolinium-labeled albumin could detect more subtle changes in coronary microvascular permeability such as those induced by noninjurious pharmacological methods.
Wild type male C57Bl/6 mice (n = 7) were imaged at 7T. Mice were anesthetized with 1.25% isoflurane and maintained at 36 ± 0.5°C during MRI. T1 mapping was performed at baseline and at 7, 14, 21, and 28 minutes after administering gadolinium-labeled albumin (4 mL/kg; Galbumin, BioPal, Worcester, MA) and, in a separate session, at the same times without administering contrast agent. Control studies without pharmacologically increasing permeability and studies where LNAME (2 mg/kg) and endothelin-1 (ET-1) (1 nmol/kg) were injected 3 and 10 minutes after baseline imaging to increase coronary microvascular permeability  were performed. Compressed-sensing accelerated (rate 2) spiral Look-Locker imaging was used for T1 mapping. The partition coefficient, defined as the ratio of contrast agent concentration in the myocardium to that in the blood, was used to quantify microvascular permeability.
T1 mapping with gadolinium-labeled albumin can detect pharmacologically-induced changes in coronary microvascular permeability. These methods hold potential for the serial noninvasive assessment of the coronary microvasculature in preclinical models of heart disease and for studies evaluating potentially protective therapies for the microvasculature. Future work will investigate the use of clinically-applicable agents such as albumin-binding gadolinium (Ablavar, Lantheus, MA) as a means to potentially translate these methods for studies of coronary microvascular disease in human patients.
- Filep J, et al: BJP. 1993Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.